

Case Study

VEEDA ONCOLOGY CAN MAXIMIZE ENROLLMENT AND PROVIDE QUALITY, TIMELY DATA TO PHARMA

Tumor type: Small Cell Lung Cancer

Line of Treatment: 2nd line

Trial Stats

- Number of Veeda Sites: 10
- Number of US sites: 61
- Number of Veeda patients contracted to enroll: 30
- Number of Veeda patients enrolled: 45
- Date opened to enrollment: March 03, 2008
- First patient enrolled: March 31, 2008
- Enrollment completion: December 21, 2009

Challenges for Veeda

- Small Cell Lung Cancer accounts for only about 10% of the lung cancer patient population – Few patients
- Small Cell Lung Cancer is a very fast growing tumor thus the patient cannot wait long to be treated – Small window to confirm eligibility
- Although Veeda provided 10 interested sites, the sponsor took an in ornate amount of time to “preapprove” so we could get them open and begin accruing

Enrollment Cap Increased

- Accruals exceeded expectations with enrollment surpassing our initial target of 30 patients, reaching a final total of 45 patients

Successes for Veeda

- Enrolled a patient within 28 days of opening trial
- Every site enrolled at least one patient
- One site was in the Top 5 performers with regard to Data Entry and Query Management
- Within 4 months of opening the trial, two sites were praised by the Sponsor for consenting 100% of their patients to PK and PGX sampling
- Praise was received from Sponsor regarding our timely communication with CRAs and adherence to Sponsor requests in a timely manne